Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2002-07-18
2008-11-04
Wehbe, Anne Marie S (Department: 1633)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S320100, C435S325000, C530S350000
Reexamination Certificate
active
07446185
ABSTRACT:
A recombinant polynucleotide encoding a Her2
eu target antigen is provided, as is a recombinant Her2
eu target antigen polypeptide. Also provided are methods of using such a recombinant polynucleotide to express a Her2
eu target antigen in a cell. In addition, methods are provided for using the recombinant polynucleotide or the recombinant polypeptide to stimulate an immune response in a subject against cancer that expresses Her2
eu. Methods of making a target antigen also are provided.
REFERENCES:
patent: 5643576 (1997-07-01), Johnston et al.
patent: 7198920 (2007-04-01), Cheever et al.
Wei et al. Protection Against Mammary Tumor Growth by Vaccination with Full-Length, Modified Human ErbB-2 DNA International Journal of Cancer 81:748-754, 1999.
Bargmann and Weinberg (Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene, PNAS, 1988 85:5394-5398).
Bell et al (Rotational Coupling of the Transmembrane and Kinase Domains of the Neu receptor Tyrosine Kinase. Molecular Biology of the Cell, 2000. 11:3589-3599).
Angelopoulou, K. et al, “p53 Gene Mutation, Tumor p53 Protein Overexpression, and Serum p53 Autoantibody Generation in Patients with Breast Cancer”,Clinical Biochemistry, vol. 33, No. 1, pp. 53-62, 2000.
Barratt=Bpues. S.M., “Maturation and Trafficking of Monocyte-Derived Dendritic Cells in Monkeys: Implications for Dendritic Cell-Based Vaccines”,The American Association of Immunologists, vol. 164, pp. 2487-2495, 2000.
Caley, I.J. et al, “Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy”,Vaccine, vol. 17, pp. 3124-3135, 1999.
Davis, N.L. et al, “A Viral Vaccine Vector That Expresses Foreign Genes in Lymph Nodes and Protects against Mucosal Challenge”,Journal of Virology, vol. 70, No. 6, pp. 3781-3787, 1996.
Disis, M.L. et al., “Generation of Immunity to the HER-2
euOncogenic Protein in Patients with Breast and Ovarian Cancer Using a Peptide-based Vaccine”,Clinical Cancer Research, vol. 5, pp. 1289-1297, 1999.
Disis, M.L, et al, “Delayed-Type Hypersensitivityy Response Is a Predictor of Peripheral Blood T-Cell Immunity after HER-2
eu Peptide Immunization”,Clinical Cancer Research, vol. 6, pp. 1347-1350, 2000.
Fong, L. Engleman, Ed., “Dendritic Cells in Cancer Immunotherapy”,Annu. Rev. Immunol., vol. 18, pp. 245-273, 2000.
Hevey, M. et al., “Marburg Virus Vaccines Based upon Alphavirus Replicons Protect Guinea Pigs and Nonhuman Primates”,Virology, vol. 251, pp. 28-37, 1998.
MacDonald, G. and Johnson, R., “Role of Dendritic Cell Targeting in Venezuelan Equine Encephalitis Virus Pathlogenesis”,Journal of Virology, vol. 74, No. 2, pp. 914-922, 2000.
Marincola, F. M. et al, “Escape of Human Solid Tumors from T-Cell Recognition: Molecular Mechanisms and Functional Significance”,Advances in Immunology, vol. 74, pp. 181-273, 2000.
Montoya, M. and del Val, M., “Intracellular Rate-Limiting Steps in MHC Class I Antigen Processing”,The American Association of Immunologists, vol. 163, pp. 1914-1922, 1999.
Morse, M.A., et al, “Migration of Human Dendritic Cells after Injection in Patients with Metastatic Malignancies”,Cancer Research, vol. 59, pp. 56-58, 1999.
Riker, A. et al., “Immune selection after antigen-specific immunotherapy of melanoma”,Surgery, vol. 126, No. 2, pp. 112-120, 1999.
Sandmaier, B.M. et al., “Evidence of a Cellular Immune Response Against Sialyl-Tn in Breast and Ovarian Cancer Patients After High-Dose Chemotherapy, Stem Cell Rescue, and immunization with Theratope STn-KLH Cancer Vaccine”,Journal of Immunotherapy, vol. 22, pp. 54-66, 1999.
Slinghuff, Jr., C.L. et al., “Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens”,Cancer Immunol Immunother, vol. 48, pp. 661-672, 2000.
Tuttle, T.M. et al., “Proliferative and Cytokine Responses to Class II HER-2
eu-associated Peptides in Breast Cancer Patients”,Clinical Cancer Research, vol. 4, pp. 2015-2024, 1998.
Vitale, M. et al., “HLA Class I Antigen and Transporter Associated with Antigen Processing (TAP1 and TAP2) Down-Regulation in High-Grade Primary Breast Carcinoma Lesions”,Cancer Research, vol. 58, pp. 737-742, 1998.
Yewdell, J.W., et al., “Mechanisms of Exogenous Antigen Presentation by MHC Class I Molecules in Vivo: Implications for Generating CD8+ T Cell Responses to Infectious Agents, Tumors, Transplants, and Vaccines”,Advances in Immunology, vol. 73, pp. 1-77, 1999.
GenBank 017003 Houliston, R.S. et al., “Characterization of the proto-oncogenic and mutant forms of the transmembrane region of Neu in micelles”,J. Biol. Chem., vol. 79, No. 23, pp. 24073-24080, 2004.
Entrez P06494 Bargmann, C.I. et al., “The neu oncogene encodes an epidermal growth factor receptor-related protein”,Nature, vol. 319, pp. 226-230, 1986.
Entrez P04626 Yamamoto, T. et al., “Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor”,Nature, vol. 319, pp. 230-234, 1986.
GenBank 004448 Ueda, Y. et al., “HER2 signaling enhances 5′UTR-mediated translation of c-Myc mRNA”,J. Biol. Chem., vol. 279, No. 23, pp. 24505-24513, 2004.
DLA Piper (LLP) US
The Regents of the University of California
Wehbe Anne Marie S
LandOfFree
Her2/neu target antigen and use of same to stimulate an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Her2/neu target antigen and use of same to stimulate an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Her2/neu target antigen and use of same to stimulate an... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4042757